Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor: Amgen
Terminated
The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.
Other terminated trials from Amgen
Other Ulcerative Colitis trials with similar outcome
Listed as NCT04987307, this PHASE2 trial focuses on Ulcerative Colitis and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 34 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
34 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Terminated PHASE2
-
Dec 2024 — Sep 2025 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
▶ Show 29 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Oct 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .